Health Trials

Generalized Pustular Psoriasis Registry in Costa Rica

ConditionsGeneralized Pustular PsoriasisGeneralized Pustular Psoriasis (GPP)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCaja Costarricense de Seguro Social

About this trial

The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:

What are the clinical, epidemiological, and therapeutic characteristics of patients with generalized pustular psoriasis registered in the country, and how do these relate to disease severity and evolution?

Patients with GPP receiving routine dermatologic care in participating centers will have their demographic, clinical, severity, comorbidity, and treatment data recorded using a standardized case report form. Clinical assessments (e.g., GPPASI, PASI/BSA, DLQI), laboratory results, triggers, complications, and therapies will be documented and updated during periodic follow-up visits as part of usual care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed diagnosis of generalized pustular psoriasis (GPP) established by a board-certified dermatologist based on compatible clinical and/or histopathologic criteria.

Registered diagnosis of GPP in the institutional electronic health record system (EDUS code L401) during the study period.

Patients of any age and sex receiving care within participating centers of the Costa Rican Social Security system.

Availability of clinical information sufficient for registry data entry and follow-up according to routine care.

Disqualifiers

Patients without a confirmed diagnosis of generalized pustular psoriasis (GPP) or with alternative pustular dermatoses (e.g., acute generalized exanthematous pustulosis) not meeting GPP diagnostic criteria.

Absence of verifiable diagnosis in the institutional electronic health record (EDUS) or insufficient documentation to confirm GPP.

Patients whose clinical records lack the minimum data required for registry variables or follow-up within routine care.

Trial population

The study population comprises patients of any age and sex with a confirmed diagnosis of generalized pustular psoriasis (GPP) receiving routine dermatologic care within participating centers of the Costa Rican Social Security (CCSS) health system. Eligible individuals are identified through the institutional electronic health record (EDUS) and enrolled in the national GPP registry during the study period. The population reflects real-world clinical practice across tertiary and regional referral hospitals, including both prevalent and incident GPP cases with varying disease duration, severity, comorbidity profiles, and exposure to conventional systemic and biologic therapies. Data are derived exclusively from standard clinical evaluations and follow-up visits conducted as part of usual care.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Disease course and evolution

Characterized by frequency of flares, presence of systemic complications, and need for hospitalization during follow-up, as recorded in standardized registry visits.

Time frame
5 years
2

Clinical severity of generalized pustular psoriasis

Assessed by the Generalized Pustular Psoriasis Area and Severity Index (GPPASI) recorded during routine clinical evaluations.

Time frame
5 years
3

Change in Generalized Pustular Psoriasis Area and Severity Index

Change from baseline in Generalized Pustular Psoriasis Area and Severity Index score as a measure of clinical severity over time.

Time frame
5 years
4

Change in Body Surface Area Affected

Change from baseline in percentage of Body Surface Area affected by psoriasis.

Time frame
5 years

Secondary outcomes

1

Clinical severity of generalized pustular psoriasis

Assessed by the PASI (Psoriasis Area Severity Index) recorded during routine clinical evaluations.

Time frame
5 years
2

Change in Psoriasis Area and Severity Index

Change from baseline in Psoriasis Area and Severity Index score as a measure of cutaneous disease severity.

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Caja Costarricense de Seguro Social

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: